... June C, Zhang PJ:Targeting HER -2/ neu in early breastcancer development using dendriticcells with staged interleukin- 12 burst secretion. Cancer Res 20 07,67:18 42- 18 52. 8. Matkowski R, Gisterek ... human breast cancer. Breast 20 08,17:604-610.10. Kominsky SL, Hobeika AC, Lake FA, Torres BA, Johnson HM: Down-regulation of neu/HER -2 by interferon-gamma in prostate cancer cells. Cancer Res 20 00, ... progressed to HER -2/ neunegative breastcancer under HER -2/ neu-specific immune pressure.Methods: We conducted a pilot study in patients with HER -2/ neu positive and HER -2/ neu negative breast cancersas...
... progressed to HER -2/ neunegative breastcancer under HER -2/ neu-specific immune pressure.Methods: We conducted a pilot study in patients with HER -2/ neu positive and HER -2/ neu negative breast cancersas ... Massey Cancer Center, 401 College Street, Richmond VA 23 298,USA. 2 Department of Pathology, Virginia Commonwealth University Massey Cancer Center, 120 0 E. Marshall Street, Richmond VA 9806 62, USA.3Department ... patientsOf 12 patients with HER -2/ neu negative breast cancers(stages I-IIIA) ten patients showed HER -2/ neu-specificIFN-g producing T cell responses (Figure 1A). Allthree patients with HER -2/ neu...
... treated for metastatic breastcancer in 4 French cancer centres. The diagnosis of metastasis was made between 19 92 and 20 02. A total of 7 72 patients received first-line chemotherapy [4]. Because ... Minjoz, 25 000 Besancon France. Xavier.pivot@univ-fcomte.fr Received: 20 08.03.13; Accepted: 20 08.05.04; Published: 20 08.05.05 The present study was conducted in patients with metastatic breast cancer. ... AM et al. Cancer incidence and mortality in France over the period 1978 -20 00. Rev Epidemiol Sante Publique 20 03;51(1 Pt 1):3-30 2. Dickson R, Pestell R, Lippman M. Metastatic breast cancer. ...
... practice.AbbreviationsFA -2: Foetal antigen 2; CA15.3: Cancer antigen 15.3; CEA: Carcinoembryonicantigen; PBC: Primary breast cancer; LAPC: Locally advanced primary breast cancer; ABC: Advanced breast cancer; ... in breast cancer. Anticancer Res 1996, 16 :22 89-93.11. Cheung KL, Graves CRL, Robertson JFR: Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev 20 00, ... and womenwith breastcancer which was still confined to the breast (ie PBC and LAPC) (Tables 1 and 2) . Nevertheless, whenall stages of cancer were taken into consideration, FA -2 levels appeared...
... brachytherapy. In thisPublished: 2 March 20 09World Journal of Surgical Oncology 20 09, 7 :24 doi:10.1186/1477-7819-7 -24 Received: 17 December 20 08Accepted: 2 March 20 09This article is available ... conventional postopera-tive whole -breast radiotherapy after breast- conservingsurgery for the management of early -stage invasive breast cancer (a trial update). Amer J Surg 20 07, 194:507-510.19. Vaidya ... report of intra-operative radiotherapy (IORT) in limited -stage breast can-cers that are conservatively treated. Eur J Cancer 20 01,37(17) :21 78 -21 83.18. Holmes DR, Baum M, Joseph D: The targit trial:...
... Global cancer statistics, 20 02. CA Cancer J Clin 20 05, 55 (2) :74-108. 2. Zheng Y, Li DL, Xiang YM, Li XJ: The status and trend of breast cancer incidence in Shanghai. J Surg Concepts Pract 20 01,6 :21 9 -22 1.3. ... amplified Her -2 FISH non-amplified Concordance by IHC Discordance by IHC0 and 1+ (n = 26 ) 5 21 (21 /26 )80.8% (5 /26 )19 .2% 2+ (n = 10) 7 3 (7/10)70.0% (3/10)30.0%3+ (n = 14) 13 1 (13/14) 92. 9% (1/14)7.1%IHC ... Peng JW: Erb-b2amplification by fluorescence in situ hybridization in breast cancer specimens read as 2+ in immunohistochemical analy-sis. Am J Clin Pathol 20 05, 124 (1):97-1 02. 22 . Kuo SJ, Wang...